Kidney involvement is common in systemic lupus erythematosus (SLE) and is a major
cause of morbidity and mortality.
1
About 50% to 70% of adults and 37% to 82% of children with SLE develop lupus nephritis
(LN).
2
A kidney biopsy is generally performed to confirm a diagnosis of LN and to inform
treatment in SLE patients who develop proteinuria with or without hematuria and/or
impaired kidney function. Proteinuria is considered to be the key clinical diagnostic
marker of LN, and in the absence of proteinuria above a certain threshold, kidney
biopsies in SLE patients are often not performed. For example, the current American
College of Rheumatology (ACR) guidelines suggest that a kidney biopsy be performed
in patients with proteinuria >1.0 g/d, or proteinuria >0.5 g/d accompanied by hematuria
or cellular casts.
3
However, there have been a handful of reports describing significant kidney pathology
in SLE patients with no or minimal proteinuria,
4
,
5
raising the question of what constitutes an appropriate threshold for performing a
kidney biopsy. We examined proteinuria levels at the time of kidney biopsy in our
LN population to determine whether the proteinuria threshold for biopsy should be <0.5−1
g/d.
We characterized 222 SLE patients who underwent a kidney biopsy for suspicion of LN
between 2008 and 2017 at the Hospital de Clinicas, University of Buenos Aires. Most
patients (79%) had proteinuria ≥0.5g/d, and all except 7 patients had evidence of
glomerular hematuria (acanthocytes) on examination of the urine sediment. However,
46 patients with a urine protein level <0.5 g/d underwent biopsy. All of these patients
had glomerular hematuria, and 5 had a serum creatinine concentration >1 mg/dl (1.1−1.3
mg/dl). All patients were Hispanic and of European ancestry. The demographic and clinical
characteristics of the patients with low (<0.5 g/d) proteinuria and the patients with
proteinuria (≥ 0.5 g/d) are compared in Table 1, and the kidney biopsy findings are
listed in Table 2. The subgroups of patients with low proteinuria plus a serum creatinine
concentration >1 mg/dl and of patients with very low proteinuria (<0.25 g/d) are described
in Table 3.
Table 1
Cohort demographics, clinical characteristics, and laboratory data at biopsy
Cohort characteristics
Proteinuria <0.5 g/d (n = 46)
Proteinuria ≥0.5 g/d (n = 176)
P valuea
Female
36 (78.3)
155 (88)a
0.097
Age, yr
31.5 (18–65)
32 (16–66)
0.72
Duration of lupus, mo
12 (2–60)
11 (1–168)
0.64
Glomerular hematuria present
46 (100)
169 (96)
0.36
Proteinuria, g/d
0.23 (0.0–0.42)
3.60 (0.5–20)
<0.0001
Serum creatinine, mg/dl
0.70 (0.4–1.3)
0.9 (0.46–7.8)
<0.0001
ANA-positive,
46 (100)
176 (100)
—
Anti-dsDNA–positive
31 (67.4)
114 (64.8)
1
C3, mg/dl
66 (15–174)
69 (14–180)
0.97
C4, mg/dl
12 (1–43)
9 (1–46)
0.89
ANA, anti-nuclear antibody; anti-dsDNA, anti−double-stranded DNA antibody; C3, complement
C3; C4, complement C4.
Data are expressed as number of patients (% of group) or median (range).
a
Comparing patients with proteinuria <0.5 g/d to patients with proteinuria ≥0.5 g/d.
Table 2
Histologic findings at biopsy
Histologic parameter
Proteinuria <0.5 g/d (n = 46)
Proteinuria ≥0.5 g/d (n = 176)
P valuea
ISN/RPS class
II
5 (10.9)
0
—
III
14 (30.4)
18 (10.2)
0.002
IV
21 (45.7)
135 (76.7)
0.0001
V
2 (4.3)
3 (1.7)
—
III or IV +V
4 (8.7)
19 (10.8)
—
VI
0
1 (0.6)
—
Activity index
6 (0−14)
9 (1−21)
<0.0001
Chronicity index
2 (0−4)
3 (0−8)
<0.0001
ISN/RPS, International Society of Neurology/Renal Pathology Society.
Data are expressed as number of patients (% of group) or as median (range).
a
Comparing patients with proteinuria <0.5 g/d to patients with proteinuria ≥0.5 g/d.
Table 3
Demographic, clinical, and histologic findings of patients with very low levels of
proteinuria
Cohort characteristics
Proteinuria <0.25 g/d (n = 25)
Both proteinuria <0.25 g/d and serum creatinine≥1 mg/dl (n = 5)
Both proteinuria <0.25 g/d and serum creatinine <1 mg/dl (n = 20)
P valuea
Female, %
21 (84)
5 (100)
16 (80)
NS
Age, yr
32 (18–65)
24 (22–42)
32 (18–65)
NS
Duration of lupus, mo
12 (2–56)
12 (4–44)
5 (2–56)
NS
Glomerular hematuria present
25 (100)
5 (100)
20 (100)
NS
Proteinuria, g/d
0.05 (0.05–0.23)
0.20 (0.05–0.23)
0.05 (0.05–0.22)
NS
Serum creatinine, mg/dl
0.70 (0.5–1.1)
1.0 (1.0–1.1)
0.63 (0.5–0.9)
0.0008
ANA-positive
25 (100)
5 (100)
20 (100)
NS
Anti-dsDNA–positive
19 (76)
4 (80)
15 (75)
NS
C3, mg/dl
64 (15–174)
44 (15–79)
87.5 (20–174)
0.032
C4, mg/dl
12 (1–43)
3 (1–14)
12.5 (1–43)
NS
Activity index
5 (0–10)
6 (6–7)
4 (0–10)
NS
Chronicity index
2 (0–4)
2 (2–3)
1 (0–4)
NS
ISN/RPS class II
5 (20)
0 (0)
5 (25)
NS
ISN/RPS class III
6 (24)
1 (20)
5 (25)
ISN/RPS class III+V
1 (4)
0 (0)
1 (5)
ISN/RPS class IV
12 (48)
4 (80)
8 (40)
ISN/RPS class V
1 (4)
0 (0)
1 (5)
ANA, anti-nuclear antibody; anti-dsDNA, anti–double-stranded DNA antibody; C3, complement
C3; C4, complement C4; ISN/RPS, International Society of Neurology/Renal Pathology
Society; NS, not significant.
Data are expressed as number of patients (% of group) or as median (range).
a
Compares patients with proteinuria <0.25 g/d with a serum creatinine level of ≥1 mg/dl
and those with proteinuria <0.25 g/d and a serum creatinine of <1mg/dl. χ2, Mann–Whitney,
and Fisher exact test used where appropriate.
About 85% of the patients with proteinuria <0.5 g/d and 76% with proteinuria <0.25
g/d had class III or IV (±V) LN. None of these patients had class I LN, and only 11%
and 20% had class II in the <0.5/d and <0.25 g/d proteinuria groups, respectively.
The patients with low proteinuria generally had moderate histologic activity, with
only 7 (15%) having an activity index ≤1. In addition, despite no prior history of
nephritis, most of the patients with low proteinuria had already accrued chronic kidney
damage, and only 8 (17%) had a chronicity index of 0. Histologic activity and chronicity
were significantly worse in the patients with >0.5 g/d proteinuria. In this group,
2 patients had an activity index of 1 and the rest were all ≥2. Similarly, 2 patients
had a chronicity index of 0, and the rest were ≥1.
Compared to the SLE patients with >0.5 g/d proteinuria, there were numerically more
male patients in the low-proteinuria group, but this was not significant. The overall
duration of SLE was the same for both groups, with a median of about 1 year, but a
very wide range. LN was diagnosed within 2 months of an SLE diagnosis in 15% of the
low-proteinuria patients and 20% of the patients with >0.5 g/d proteinuria. Patients
at both levels of proteinuria were of similar age, all were anti-nuclear antibody–positive,
and there were no differences between groups in complement consumption or the proportion
of patients who were double-stranded DNA antibody–positive. However, patients with
proteinuria <0.5 g/d did have significantly better kidney function than patients with
proteinuria >0.5 g/d.
These observations demonstrate that in patients with SLE and glomerular hematuria,
the kidney may harbor significant pathology without much proteinuria. One interpretation
of these findings is that the patients were identified very early in the course of
their LN. Although that may be the case and although it cannot be determined from
our cohort, their overall duration of SLE was 12 months, their kidney biopsy samples
showed more than minimal histologic activity, and their kidneys already had evidence
of chronic damage. These findings support making an early diagnosis of LN with rapid
treatment to avoid chronic renal injury and progressive kidney dysfunction.
6
,
7
It is important to emphasize that our patients do not have silent lupus nephritis,
which describes patients with no urinary abnormalities and proteinuria ≤300 mg/24
h. Between 60% and 70% of patients with silent LN were found to have class I or II
LN histology, whereas only 15% to 20% had class III or IV.
5
,
8
In contrast, class IV LN was the most common International Society of Nephrology/Renal
Pathology Society (ISN/RPS) class found in our patients with glomerular hematuria
(46%), closely followed by class III LN (30%). Similarly, class III or IV LN was found
in 14 of 24 (58%) patients with SLE, proteinuria <0.25 g/d, and an active urine sediment,
4
and in 57% of 21 patients who had a kidney biopsy for 24-h proteinuria <1 g/d with
or without hematuria.
9
This study has several limitations. It is a retrospective analysis and cannot be used
to define the incidence or prevalence of proliferative LN in patients with minimal
proteinuria. There were too few patients with class II or V LN to be able to identify
predictors to differentiate LN classes in a population of patients with glomerular
hematuria and low-grade proteinuria. Finally, and most importantly, all of the patients
with class III and IV LN were treated aggressively with corticosteroids and an immunosuppressive
agent (cyclophosphamide or mycophenolate mofetil), precluding any determination of
whether patients with these characteristics may respond adequately to less intense
immunosuppression.
In summary, patients with lupus and evidence of an active urine sediment but low levels
of proteinuria (<0.5 g/d) may have important kidney pathology that warrants aggressive
treatment. Despite current guidelines that recommend a proteinuria threshold of >0.5
to 1 g/d, a diagnostic kidney biopsy in SLE patients with low-grade proteinuria should
be considered.
Disclosure
All the authors declared no competing interests.